Pierre-Henri Benhamou

Dr. Pierre-Henri Benhamou is Co-Founder, Chairman and Chief Executive Officer of DBV Technologies S.A. Dr. Benhamou co-founded DBV Technologies in 2002, and has served as Chief Executive Officer from 2002 to the present and Chairman of the board of directors since the initial public offering on NYSE Euronext Paris in March 2012. With Professor Christophe Dupont and Bertrand Dupont, he described for the first time and patented the epicutaneous method of immunotherapy and explored with the scientific team the wide range of applications of the method. Dr. Benhamou is a physician, specializing in pediatric gastroenterology. He has held numerous clinical and academic positions. He received the Altran Foundation Prize for Innovation in 2003 for his work on the development of diagnostic patch tests. Dr. Benhamou has published numerous papers and originated key scientific collaborations for DBV Technologies, and has been instrumental in forming the scientific advisory board. Dr. Benhamou received an M.D. in medicine from Faculte de Medecine de Paris in 1984 and his specialization degree in pediatrics in 1987. The board of directors believes that Dr. Benhamou’s leadership, deep knowledge of the company and scientific experience will allow him to drive DBV to success.